Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 13

Results For "synthetic"

128 News Found

India restricts export of Rapid Antigen Test Kits used to detect Covid 19
Policy | August 16, 2021

India restricts export of Rapid Antigen Test Kits used to detect Covid 19

The notification implies that any export of Rapid Antigen Kit will require a licence or permission from DGFT


Lonza extends collaboration with Biopharma company
News | July 19, 2021

Lonza extends collaboration with Biopharma company

As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies


CSIR join hands with SUVEN Pharmaceuticals
Drug Approval | June 11, 2021

CSIR join hands with SUVEN Pharmaceuticals

The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL


Glenmark receives ANDA approval for Icatibant Injection
News | May 25, 2021

Glenmark receives ANDA approval for Icatibant Injection

This marks Glenmark's first synthetic decapeptide injectable approval


Piramal Enterprises forays into peptide with Hemmo Pharma : ICICI Securities
News | April 05, 2021

Piramal Enterprises forays into peptide with Hemmo Pharma : ICICI Securities

ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E


Piramal Pharma to acquire 100% stake in Hemmo for Rs 775 Cr
News | April 01, 2021

Piramal Pharma to acquire 100% stake in Hemmo for Rs 775 Cr

This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs


From farm to pharmaceuticals: Traditional medicine in a phytopharma avatar
News | March 10, 2021

From farm to pharmaceuticals: Traditional medicine in a phytopharma avatar

Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.


Pharma industry bullish on complex generics and biosimilars
News | February 25, 2021

Pharma industry bullish on complex generics and biosimilars

While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side